AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global RNAi Technology Market 2020-2024 | Evolving Opportunities with Alnylam Pharmaceuticals Inc. and Arbutus Biopharma Corp. | Technavio

January 10, 2020 GMT
Global RNAi Technology Market 2020-2024 | Evolving Opportunities with Alnylam Pharmaceuticals Inc. and Arbutus Biopharma Corp. | Technavio
Global RNAi Technology Market 2020-2024 | Evolving Opportunities with Alnylam Pharmaceuticals Inc. and Arbutus Biopharma Corp. | Technavio

LONDON--(BUSINESS WIRE)--Jan 9, 2020--

Technavio has been monitoring the global RNAi technology market since 2019 and the market is poised to grow by USD 1.96 billion during 2020-2024, progressing at a CAGR of around 22% during the forecast period. Request free sample pages

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200109005705/en/

Technavio has announced its latest market research report titled global RNAi technology market 2020-2024 (Graphic: Business Wire)

Read the 168-page report with TOC on “RNAi Technology Market Analysis Report by Application (Cancer, Infectious diseases, Ophthalmic diseases, Genetic diseases, and Other diseases), Geography (Asia, Europe, North America, and ROW), and the Segment Forecasts, 2020-2024”.

https://www.technavio.com/report/RNAi-technology-market-industry-analysis

The market is driven by the increasing adoption of RNAi technology for undruggable targets. In addition, recent advances in whole-genome RNAi screening is anticipated to boost the growth of the RNAi technology market.

RNAi technology is emerging as a promising therapeutic platform for the treatment of various diseases. This is due to efficient delivery mechanisms, high specificity in the targeted section, and the knockdown approach and safety of RNAi-based therapies. Moreover, RNAi technology has made every gene in the human genome as a druggable target, which is creating new opportunities for vendors to develop a wide range of targeted therapies. This is attracting many drug manufacturers to focus on the development of RNAi-based targeted cancer therapies. Several early-phase trials have reported clinical responses in the case of RNAi therapies directed against targets such as Kinesin spindle protein (KSP) and vascular endothelial growth factor (VEGF). Therefore, the increasing adoption of RNAi technology for undruggable targets is expected to fuel market growth during the forecast period.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five RNAi Technology Market Companies:

Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals Inc. operates in a single reporting segment, the discovery, development, and commercialization of RNAi therapeutics. The company offers ONPATTRO (patisiran) and GIVLAARITM (givosiran), and other RNAi therapeutics such as Fitusiran, Inclisiran, Lumasiran, and Vutrisiran in late stage (Phase 2 to Phase 4) clinical development pipeline.

Arbutus Biopharma Corp.

Arbutus Biopharma Corp. offers RNAi based therapeutic solutions for drug development, discovery, and commercialization to patients suffering from hepatitis B infection. Some of the key offerings of the company include LNP Delivery Platform and RNA Trigger Technologies.

Arrowhead Pharmaceuticals Inc.

Arrowhead Pharmaceuticals Inc. uses RNAi-based technologies in the development of therapeutics for treating intractable diseases. The company also offers licenses for its patented RNAi technology through collaboration. Targeted RNAi Molecule (TRiM) Platform is the key offering of the company.

Bio-Rad Laboratories Inc.

Bio-Rad Laboratories Inc. operates the business across segments such as Life Science and Clinical Diagnostics. Some of the key offerings of the company include siLentFect Lipid Reagent for RNAi and siLentMer.

Dicerna Pharmaceuticals Inc.

Dicerna Pharmaceuticals Inc. develops RNAi-based therapeutics using GalXC RNAi platform. The company also offers licensed use of their platforms through collaboration. GalXC Technology Platform is the key offering of the company.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio’s SUBSCRIPTION platform

RNAi Technology Application Outlook (Revenue, USD Billion, 2020 - 2024)

RNAi Technology Regional Outlook (Revenue, USD Billion, 2020 - 2024)

Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report

Related Reports on Healthcare include:

Global Cancer Biologics Market – Global cancer biologics market by product (monoclonal antibodies, vaccines, cell and gene therapy, and others) and geography (Asia, Europe, North America, and ROW).

Global RNA and DNA Extraction Kit Market – Global RNA and DNA extraction kit market by product (RNA extraction kit and DNA extraction kit) and geography (Asia, Europe, North America, and ROW).

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com

View source version on businesswire.com:https://www.businesswire.com/news/home/20200109005705/en/

CONTACT: Technavio Research 

Jesse Maida 

Media & Marketing Executive 

US: +1 844 364 1100 

UK: +44 203 893 3200 

www.technavio.com

Follow Us: LinkedIn | Twitter 

KEYWORD:

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH

SOURCE: Technavio Research

Copyright Business Wire 2020.

PUB: 01/09/2020 09:00 PM/DISC: 01/09/2020 09:00 PM

http://www.businesswire.com/news/home/20200109005705/en